BiondVax is an innovative biopharmaceutical company developing a Universal Flu Vaccine, designed to provide multi-season and multi-strain protection against most human influenza virus strains, including both seasonal and pandemic flu strains.
The company’s headquarters are in Israel, in the science and technology park adjacent to the Weismann Institute. The address: 14 Einstein Street, Ness Ziona, Israel. The company’s state-of-the-art GMP facility in Ness-Ziona houses its laboratories, production facilities and offices.
BiondVax has a team of 14 includes scientists, technicians, researchers, and administrative staff.
BiondVax legal counsel is Pearl Cohen Zedek Latzer Baratz, based in Israel and can be contacted on +972-3-607 3777.
BiondVax works with Ernst & Young in Israel and can be contacted on +972 3 623 2525.
BiondVax works with Gelbart-Kahana in Israel for its domestic investor relations program and GK, a subsidiary of Gelbart-Kahana for its international investor relations program. To contact investor relations please e-mail: email@example.com or call +972 3 607 4717 in Israel or +1 646 201 9246 internationally.